Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 31.19 USD 1.3% Market Closed
Market Cap: 1B USD
Have any thoughts about
Collegium Pharmaceutical Inc?
Write Note

Intrinsic Value

The intrinsic value of one COLL stock under the Base Case scenario is 47.46 USD. Compared to the current market price of 31.19 USD, Collegium Pharmaceutical Inc is Undervalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

COLL Intrinsic Value
47.46 USD
Undervaluation 34%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Collegium Pharmaceutical Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for COLL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about COLL?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Collegium Pharmaceutical Inc

Provide an overview of the primary business activities
of Collegium Pharmaceutical Inc.

What unique competitive advantages
does Collegium Pharmaceutical Inc hold over its rivals?

What risks and challenges
does Collegium Pharmaceutical Inc face in the near future?

Has there been any significant insider trading activity
in Collegium Pharmaceutical Inc recently?

Summarize the latest earnings call
of Collegium Pharmaceutical Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Collegium Pharmaceutical Inc.

Provide P/S
for Collegium Pharmaceutical Inc.

Provide P/E
for Collegium Pharmaceutical Inc.

Provide P/OCF
for Collegium Pharmaceutical Inc.

Provide P/FCFE
for Collegium Pharmaceutical Inc.

Provide P/B
for Collegium Pharmaceutical Inc.

Provide EV/S
for Collegium Pharmaceutical Inc.

Provide EV/GP
for Collegium Pharmaceutical Inc.

Provide EV/EBITDA
for Collegium Pharmaceutical Inc.

Provide EV/EBIT
for Collegium Pharmaceutical Inc.

Provide EV/OCF
for Collegium Pharmaceutical Inc.

Provide EV/FCFF
for Collegium Pharmaceutical Inc.

Provide EV/IC
for Collegium Pharmaceutical Inc.

Show me price targets
for Collegium Pharmaceutical Inc made by professional analysts.

What are the Revenue projections
for Collegium Pharmaceutical Inc?

How accurate were the past Revenue estimates
for Collegium Pharmaceutical Inc?

What are the Net Income projections
for Collegium Pharmaceutical Inc?

How accurate were the past Net Income estimates
for Collegium Pharmaceutical Inc?

What are the EPS projections
for Collegium Pharmaceutical Inc?

How accurate were the past EPS estimates
for Collegium Pharmaceutical Inc?

What are the EBIT projections
for Collegium Pharmaceutical Inc?

How accurate were the past EBIT estimates
for Collegium Pharmaceutical Inc?

Compare the revenue forecasts
for Collegium Pharmaceutical Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Collegium Pharmaceutical Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Collegium Pharmaceutical Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Collegium Pharmaceutical Inc compared to its peers.

Compare the P/E ratios
of Collegium Pharmaceutical Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Collegium Pharmaceutical Inc with its peers.

Analyze the financial leverage
of Collegium Pharmaceutical Inc compared to its main competitors.

Show all profitability ratios
for Collegium Pharmaceutical Inc.

Provide ROE
for Collegium Pharmaceutical Inc.

Provide ROA
for Collegium Pharmaceutical Inc.

Provide ROIC
for Collegium Pharmaceutical Inc.

Provide ROCE
for Collegium Pharmaceutical Inc.

Provide Gross Margin
for Collegium Pharmaceutical Inc.

Provide Operating Margin
for Collegium Pharmaceutical Inc.

Provide Net Margin
for Collegium Pharmaceutical Inc.

Provide FCF Margin
for Collegium Pharmaceutical Inc.

Show all solvency ratios
for Collegium Pharmaceutical Inc.

Provide D/E Ratio
for Collegium Pharmaceutical Inc.

Provide D/A Ratio
for Collegium Pharmaceutical Inc.

Provide Interest Coverage Ratio
for Collegium Pharmaceutical Inc.

Provide Altman Z-Score Ratio
for Collegium Pharmaceutical Inc.

Provide Quick Ratio
for Collegium Pharmaceutical Inc.

Provide Current Ratio
for Collegium Pharmaceutical Inc.

Provide Cash Ratio
for Collegium Pharmaceutical Inc.

What is the historical Revenue growth
over the last 5 years for Collegium Pharmaceutical Inc?

What is the historical Net Income growth
over the last 5 years for Collegium Pharmaceutical Inc?

What is the current Free Cash Flow
of Collegium Pharmaceutical Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Collegium Pharmaceutical Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Collegium Pharmaceutical Inc

Current Assets 443.8m
Cash & Short-Term Investments 120m
Receivables 228.5m
Other Current Assets 95.4m
Non-Current Assets 1.2B
PP&E 20.8m
Intangibles 1.1B
Other Non-Current Assets 77.7m
Current Liabilities 459.4m
Accounts Payable 3.1m
Accrued Liabilities 356.8m
Other Current Liabilities 99.5m
Non-Current Liabilities 941.4m
Long-Term Debt 802.6m
Other Non-Current Liabilities 138.8m
Efficiency

Earnings Waterfall
Collegium Pharmaceutical Inc

Revenue
599.2m USD
Cost of Revenue
-225.6m USD
Gross Profit
373.7m USD
Operating Expenses
-180.2m USD
Operating Income
193.5m USD
Other Expenses
-104.9m USD
Net Income
88.6m USD

Free Cash Flow Analysis
Collegium Pharmaceutical Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

COLL Profitability Score
Profitability Due Diligence

Collegium Pharmaceutical Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional ROE
Exceptional 3-Years Revenue Growth
Positive 3-Year Average ROE
51/100
Profitability
Score

Collegium Pharmaceutical Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

COLL Solvency Score
Solvency Due Diligence

Collegium Pharmaceutical Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Short-Term Solvency
Positive Net Debt
High D/E
25/100
Solvency
Score

Collegium Pharmaceutical Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

COLL Price Targets Summary
Collegium Pharmaceutical Inc

Wall Street analysts forecast COLL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for COLL is 43.1 USD with a low forecast of 37.37 USD and a high forecast of 52.5 USD.

Lowest
Price Target
37.37 USD
20% Upside
Average
Price Target
43.1 USD
38% Upside
Highest
Price Target
52.5 USD
68% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for COLL?

Click here to dive deeper.

Dividends

Collegium Pharmaceutical Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for COLL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

COLL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

1B USD

Dividend Yield

0%

Description

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

Contact

MASSACHUSETTS
Stoughton
100 Technology Center Dr
+17817133699.0
www.collegiumpharma.com

IPO

2015-05-07

Employees

152

Officers

Co-Founder, Chairman, Interim CEO & President
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.
Executive VP & CFO
Ms. Colleen Tupper
Executive VP, General Counsel, Chief Administrative Officer & Secretary
Ms. Shirley R. Kuhlmann
Executive VP & Chief Commercial Officer
Mr. Scott Dreyer
Executive VP & Chief Medical Officer
Dr. Thomas B. Smith FAAFP, M.D.
Vice President of Investor Relations
Dr. Christopher Shayne James M.D.
Show More
Executive Vice President of Strategy & Corporate Development
Mr. Bart J. Dunn
Head of Technical Operations
Mr. Scott Sudduth
Show Less

See Also

Discover More
What is the Intrinsic Value of one COLL stock?

The intrinsic value of one COLL stock under the Base Case scenario is 47.46 USD.

Is COLL stock undervalued or overvalued?

Compared to the current market price of 31.19 USD, Collegium Pharmaceutical Inc is Undervalued by 34%.

Back to Top